ARK's CRISPR Therapeutics Stake Is 10.4% — Its Innovation ETF Has An Interest Above 5%

The investment manager and Catherine D. Wood reported the same shares, with different voting and disposal powers.

Share
ARK's CRISPR Therapeutics Stake Is 10.4% — Its Innovation ETF Has An Interest Above 5%

ARK Investment Management reported a 10.4% stake in CRISPR Therapeutics, which develops gene-based treatments for serious diseases, in a passive ownership disclosure filed Friday. The position covered September 30, 2026, and ARK identified its ARK Innovation ETF as having a client interest above 5%.

One Position, Different Ownership Powers

ARK reported 10,056,844 common shares. Catherine D. Wood, ARK's chief executive and chief investment officer, reported beneficial ownership of that same position; her entry does not add another block of shares to ARK's total.

ARK had sole authority to vote 9,466,222 shares and shared authority over 143,106. Wood reported shared voting authority over 9,609,328 shares, with none under her sole authority.

The disposal powers followed a different split: ARK reported sole authority to dispose of all 10,056,844 shares, while Wood reported shared disposal authority over the full position.

ARK certified that the shares were held for ordinary business activity and not to influence the company's control. ARK Innovation ETF was the client identified as exceeding the 5% interest threshold.

ARK's concentrated ETF holdings in small and mid-sized companies have led to about 170 ownership schedules over two years.

The Gene-Editing Business Behind CRSP

CRISPR Therapeutics uses CRISPR/Cas9 editing to change targeted DNA sequences. Its programs cover blood disorders, editing delivered directly into the body, CAR T cell therapies and regenerative medicine for Type 1 diabetes.

Its most advanced product, CASGEVY, treats eligible patients with severe sickle cell disease or transfusion-dependent beta thalassemia. CRISPR develops and sells the treatment jointly with Vertex Pharmaceuticals, which leads commercialization.

CASGEVY has approval in the United States, the European Union, Great Britain, Canada, Switzerland and several Middle Eastern countries. CRISPR also works with Sirius Therapeutics on siRNA medicines and operates its own manufacturing facility in Framingham, Massachusetts.

CRISPR Therapeutics had a market capitalization of $4.1 billion in Friday trading as of 12:55 p.m. ET.

Sources

More on CRISPR Therapeutics

All CRISPR Therapeutics (CRSP) coverage →